Nicholas C DAmato
Overview
Explore the profile of Nicholas C DAmato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barton V, Christenson J, Gordon M, Greene L, Rogers T, Butterfield K, et al.
Cancer Res
. 2017 May;
77(13):3455-3466.
PMID: 28512248
Preclinical and early clinical trials indicate that up to 50% of triple-negative breast cancers (TNBC) express androgen receptor (AR) and are potentially responsive to antiandrogens. However, the function of AR...
2.
Gordon M, DAmato N, Gu H, Babbs B, Wulfkuhle J, Petricoin E, et al.
Mol Cancer Ther
. 2017 May;
16(7):1389-1400.
PMID: 28468774
The androgen receptor (AR) is widely expressed in breast cancer, and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown...
3.
DAmato N, Gordon M, Babbs B, Spoelstra N, Carson Butterfield K, Torkko K, et al.
Mol Cancer Res
. 2016 Aug;
14(11):1054-1067.
PMID: 27565181
Implications: This study suggests that AR plays a previously unrecognized role in supporting E2-mediated ER activity in ER/AR breast cancer cells, and that enzalutamide may be an effective therapeutic in...
4.
DAmato N, Rogers T, Gordon M, Greene L, Cochrane D, Spoelstra N, et al.
Cancer Res
. 2015 Sep;
75(21):4651-64.
PMID: 26363006
The ability of a cancer cell to develop resistance to anoikis, a programmed cell death process triggered by substratum detachment, is a critical step in the metastatic cascade. Triple-negative breast...
5.
Barton V, DAmato N, Gordon M, Christenson J, Elias A, Richer J
Horm Cancer
. 2015 Jul;
6(5-6):206-13.
PMID: 26201402
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) amplification. Due to the absence...
6.
Barton V, DAmato N, Gordon M, Lind H, Spoelstra N, Babbs B, et al.
Mol Cancer Ther
. 2015 Feb;
14(3):769-78.
PMID: 25713333
Triple-negative breast cancer (TNBC) has the lowest 5-year survival rate of invasive breast carcinomas, and currently there are no approved targeted therapies for this aggressive form of the disease. The...
7.
Cochrane D, Bernales S, Jacobsen B, Cittelly D, Howe E, DAmato N, et al.
Breast Cancer Res
. 2014 Jan;
16(1):R7.
PMID: 24451109
Introduction: The androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in estrogen receptor alpha (ER) negative breast cancers that retain AR....
8.
DAmato N, Howe E, Richer J
Cancer Lett
. 2012 Dec;
341(1):46-55.
PMID: 23228634
MicroRNAs (miRNAs) are small non-coding RNA molecules capable of regulating multiple target genes through repression of mRNA stability or translation. miRNAs regulate a wide variety of developmental and pathological processes,...
9.
DAmato N, Ostrander J, Bowie M, Sistrunk C, Borowsky A, Cardiff R, et al.
PLoS One
. 2012 Oct;
7(9):e45684.
PMID: 23049838
Breast cancers with a basal-like gene signature are primarily triple-negative, frequently metastatic, and carry a poor prognosis. Basal-like breast cancers are enriched for markers of breast cancer stem cells as...
10.
CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis
Vasilatos S, Broadwater G, Barry W, Baker Jr J, Lem S, Dietze E, et al.
Cancer Epidemiol Biomarkers Prev
. 2009 Mar;
18(3):901-14.
PMID: 19258476
Background: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in...